title: Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.
abstract: Severe ovarian hyperstimulation syndrome (OHSS) was recorded in 8 of 413 patients after the use of gonadotropin-releasing hormone agonists (GnRH-a) associated with gonadotropins for in vitro fertilization. Seven of the 8 patients were pregnant. Common factors associated with the development of OHSS were high serum estradiol values on the day of ovulation induction and many follicles greater than or equal to 12 mm. Based on this experience, a new therapeutic schedule was used in a group of 10 patients who, after GnRH-a and gonadotropin stimulation, were judged to be at high risk of OHSS on the day of human chorionic gonadotropin (hCG). No hCG was administered and gonadotropins were stopped. The administration of GnRH-a was continued and, after a further period of pituitary desensitization, follicular stimulation was recommended with a lower dose of gonadotropins. No cases of OHSS occurred and 3 patients became pregnant.
authors.affiliation: Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom.
authors.forename: R G
authors.initials: RG
authors.lastname: Forman
authors.forename: R
authors.initials: R
authors.lastname: Frydman
authors.forename: D
authors.initials: D
authors.lastname: Egan
authors.forename: C
authors.initials: C
authors.lastname: Ross
authors.forename: D H
authors.initials: DH
authors.lastname: Barlow
mesh_terms: D002064:Buserelin / Q000009:adverse effects* / Q000494:pharmacology; D004958:Estradiol / Q000097:blood; D005060:Europe; D005260:Female; D005307:Fertilization in Vitro / Q000187:drug effects*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D010049:Ovarian Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors; D013577:Syndrome; D017329:Triptorelin Pamoate / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D002064:Buserelin